1. Byrareddy SN*,Ayash-Rashkovsky M, Kramer VG,LeeSJ, Correll M, Novembre FJ, Villinger F, Johnson W, Gegerfelt V, Felber FK, and Ruprecht RM. Live Attenuated Rev-Independent Nef¯SIVEnhances Acquisition of Heterologous SIVsmE660 in Acutely Vaccinated Rhesus Macaques. PLoS One. 2013 Sep 30;8(9):e75556.
2. Pérez-Bercoff L, Kumar-Vudattu N,Byrareddy SN, Maeurer M, Ljungman P. IL-7 response defined by STAT5 phosphorylationin the reconstituting CMV-specific immune system after hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2013 Oct 15. doi:pii: S1083-8791(13)00452-7. 10
3. Watkins JD, Sholukh AM, Mukhtar MM,Siddappa NB, Lakhashe SK, Kim M, Reinherz EL, Gupta S, Forthal, DN, Sattentau Q, Villinger F, Corti D, Ruprecht RM, for the CAVD Project Group. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission.AIDS. 27(9):F13-F20, June 1, 2013.
4. Bachler BC, Humbert M, Palikuqi B,Siddappa NB, Lakhashe SK, Rasmussen RA, Ruprecht RM. Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol. 2013 Apr;87(8):4403-16
5. Rasmussen RA*,Siddappa NB*, Lakhashe SK*, Watkins J, Villinger F, Ibegbu C, Florese RH, Robert-GuroffM, Montefiori DC, Forthal DN, O'Connor D, Ruprecht RM; for the Clade C Program Project. High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia.AIDS.2012 Jan 14;26(2):149-55 (*Equal first authors)
6. Siddappa NB, Hemashettar H, Shanmuganathan V, Semenya A, Sweeney ED, Paul KS, Lee SJ, Secor EW, Ruprecht RM.Schistosoma mansoniEnhances Host Susceptibility to Mucosal but not Intravenous Challenge by R5 Clade C SHIV.PLoS Negl Trop Dis: 2011;5(8): e1270(Appeared in journal cover page).
7. Watkins JD*,Siddappa NB*, Lakhashe SK, Humbert M, Sholukh A, Hemashettar G, Wong YL, Yoon JK,Wang W, Novembre FJ, Villinger F, Ibegbu C, Patel K, Corti D, Agatic G, Vanzetta F, Bianchi S, Heeney JL, Sallusto F, Lanzavecchia A, Ruprecht RM. Cross-clade protection with an anti-HIV-1 V3-loop antibody in macaques mucosally challenged with simian-human immunodeficiency virus.PLoS One. 2011 Mar 31;6(3):e18207 (*Equal first authors)
8. Siddappa NB,Watkins J, Wassermann K,Wang W, KramerVG,Lakhashe S, Santosuosso M, Poznansky M,Novembre FJ, Villinger F, Else J, MontefioriDC, Rasmussen RA, RuprechtRM. R5 Clade C SHIV Strains with Tier 1 or 2 Neutralization Sensitivity: Tools to Dissect Env Evolution and to Develop AIDS Vaccines in Primate Models.PLoS One. 2010; 21;5(7):e11689.
9. Siddappa NB, Song R, Kramer VG, Chenine AL, Velu V, Ong H, Rasmussen RA, GrissonRD, Wood C, Zhang H, Kankasa C, Amara RR, Else JG, Montefiori D, Novembre,FJ, Ruprecht RM. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carriesenvfrom an infant with recent HIV clade C infection.J Virol2009; 83(3):1422-32.
10. Siddappa NB, Avinash A, Venkatramanan M, Ranga U.Regeneration of commercial nucleic acid extraction columns without the risk of carryover contamination.BioTechniques2007; 42: 188-92.
11. Siddappa NB, Venkatramanan M, Venkatesh P, Janki MV, Jayasuryan N, Desai A, Ravi V, Ranga U.Transactivation and signaling functions of Tat are not correlated:biological and immunological characterization of HIV-1 subtype-C Tat protein.Retrovirology2006; 3:53.
12. Siddappa NB,Dash PK, Mahadevan A, Desai A, Jayasuryan N, Satishchandra P, Ravi V, Shankar SK, Ranga U.Identification of unique B/C recombinant strains of HIV-1 in the southern state of Karnataka, India.AIDS2005; 19: 1426-1429.

Profile Details

NULL